Imagine a tiny chip that acts like a high-tech magnifying glass for cancer markers. It uses special light and AI to spot exactly when a lung cancer drug stops working in real-time. Instead of waiting for slow lab tests, doctors can see what is happening inside a patient's cells almost instantly.
Lung cancer patients often develop resistance to TKI drugs, but detecting this resistance currently requires slow, lab-heavy processes. This delay prevents doctors from switching treatments quickly, worsening patient outcomes.
A six-layer nano-photonic sensor including IR emitter arrays, AI-optimized surfaces, and a metamaterial detector for real-time omics analysis.
If you are an oncology clinic dealing with patients who stop responding to TKI treatments — this project developed a miniaturized bio-sensor that detects EGFR mutations quickly. This allows doctors to tailor treatments in real-time and improve patient prognosis.
If you are a drug discovery firm dealing with the high cost of failed clinical trials — this project developed a sensor compatible with organ-on-chip systems. This enables more efficient drug testing through digital twinning of biological systems.
If you are a diagnostic provider dealing with the need to move complex tests out of specialized labs — this project developed a compact, six-layer nano-photonic platform. This brings advanced omics analysis directly to the point-of-care.
Based on available project data, there is no specific pricing or cost information provided.
The project has already initiated wafer-scale production of tungsten-based emitters using hafnium carbide to boost performance, suggesting a path toward industrial scaling.
Based on available project data, specific licensing terms are not mentioned, though an Innovation Board has been established to manage innovation efforts.
The sensor is designed for point-of-care testing and is compatible with organ-on-chip systems, allowing it to be used in both clinical settings and drug testing labs.
The project period runs from 2024-01-01 to 2026-12-31, indicating it is currently in the development phase.
The consortium is highly balanced for commercialization, featuring a 50% industry ratio with 4 industrial partners, including 3 SMEs. It combines academic research from 3 universities and 1 research institute across 8 countries, ensuring a mix of deep-tech expertise in AI, MEMS, and oncology with the agility of small businesses to drive the innovation board's efforts.
Contact Universita Degli Studi di Trento
Contact us to connect with the OMICSENS Innovation Board for early licensing opportunities.
